Zogenix, Inc. (NASDAQ:ZGNX), shares soared 20.51% after the company announced that the U.S. District Court in Massachusetts has entered an order preventing a ban on Zohydro ER (opioid agonist, extended-release, oral formulation of hydrocodone bitartrate) on Constitutional grounds. Zogenix, Inc. (NASDAQ:ZGNX), shares after opening at $2.80 moved to $2.87 on last trade day and at the end of the day closed at $2.71. Company price to sales ratio in past twelve months was calculated as 11.46 and price to cash ratio as 5.25. Zogenix, Inc. (NASDAQ:ZGNX), showed a negative weekly performance of 2.09%.
Equities research analysts at Stifel Nicolaus raised their price objective on shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX), from $38.00 to $39.00 in a research note issued to investors on Friday, AnalystRatings.Net reports. Stifel Nicolaus’ price target points to a potential upside of 26.79% from the company’s current price. Auspex Pharmaceuticals Inc (NASDAQ:ASPX), shares fell 0.09% in last trading session and ended the day on $23.38.
On March 31, 2014, Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, announced full financial results for fiscal year ended December 31, 2013. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), shares moved down 9.05% in last trading session and was closed at $5.73, while trading in range of $ 5.70 – 6.45. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), year to date (YTD) performance is 63.25%.
Heron Therapeutics Inc (NASDAQ:HRTX), was downgraded byZacks to a “neutral” rating in a research report issued to clients and investors on Monday, AnalystRatings.NETreports. They currently have a $14.30 price objective on the stock. Zacks‘ price target would indicate a potential upside of 2.88% from the stock’s previous close. Heron Therapeutics Inc (NASDAQ:HRTX), weekly performance is 1.97%. On last trading day company shares ended up $11.91. Heron Therapeutics Inc (NASDAQ:HRTX), distance from 50-day simple moving average (SMA50) is -12.07%. Analysts mean target Price for the company is $24.75.
Leave a Reply